MSH6: A Non-Code RNA Molecule as A Drug Target and Biomarker (G2956)

Target Name: MSH6

NCBI ID: G2956

MSH6

MSH6: A Non-Code RNA Molecule as A Drug Target and Biomarker

MSH6 (MutL homolog 6) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its function and structure have been extensively studied, and its potential as a drug target continue to attract researchers' interest.

MSH6 is a member of the MUTL family of non-coding RNAs, which are known for their ability to interact with the protein MUTL1. MUTL1, a tumor suppressor gene, has been implicated in various diseases, including cancer. The MUTL family has also been associated with the development of neurodegenerative diseases.

MSH6 is a small RNA molecule that contains 194 amino acid residues. It is expressed in various tissues and organs, including brain, heart, liver, and muscle. MSH6 has been shown to play a role in various physiological processes, including cell growth, apoptosis, and inflammation.

One of the most significant functions of MSH6 is its role in cell apoptosis. Apoptosis is a natural process that is involved in the elimination of damaged or dysfunctional cells. MSH6 has been shown to regulate apoptosis in various cell types, including cancer cells.

MSH6 has also been shown to play a role in cell growth and development. It has been shown to promote the growth of various cell types, including cancer cells. This may contribute to the development of cancer.

MSH6 has also been shown to play a role in inflammation. It has been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, in various cell types. This may contribute to the development of inflammatory diseases.

Due to its various functions, MSH6 has been identified as a potential drug target and biomarker. Researchers have been studying its potential interactions with various drugs and trying to develop new treatments based on its unique properties.

One of the most promising potential drug targets for MSH6 is the inhibition of its activity. Researchers have been studying the effects of various drugs on MSH6 expression and have developed new compounds that can inhibit its activity. These compounds have been shown to have potential as anti-cancer and anti-inflammatory drugs.

Another promising approach to studying MSH6 is its use as a biomarker. Researchers have been studying the expression of MSH6 in various disease states, including cancer, and have developed methods to measure its expression. These methods have been used to identify new biomarkers for various diseases, including cancer.

In conclusion, MSH6 is a non-coding RNA molecule that has a wide range of functions, including regulation of cell apoptosis, growth, and inflammation. Its potential as a drug target and biomarker continue to attract researchers' interest. Further research is needed to fully understand its role in various diseases and to develop new treatments based on its unique properties.

Protein Name: MutS Homolog 6

Functions: Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. When bound, MutS alpha bends the DNA helix and shields approximately 20 base pairs, and recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. Recruited on chromatin in G1 and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated allowing a quick identification of mismatch repair to initiate the DNA mismatch repair reaction

The "MSH6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSH6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets